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14 The Journal of Thoracic and Cardiobjective: A cerebrovascular accident is a devastating adverse event in a patient
ith a ventricular assist device. The goal was to clarify the risk factors for
erebrovascular accident.
ethods: Prospectively collected data, including medical history, ventricular assist
evice type, white blood cell count, thrombelastogram, and infection, were reviewed
etrospectively in 124 patients.
esults: Thirty-one patients (25%) had 48 cerebrovascular accidents. The mean
entricular assist device support period was 228 and 89 days in patients with and
ithout cerebrovascular accidents, respectively (P  .0001). Sixty-six percent
f cerebrovascular accidents occurred within 4 months after implantation. Ac-
uarial freedom from cerebrovascular accident at 6 months was 75%, 64%, 63%,
nd 33% with the HeartMate device (Thoratec Corp, Pleasanton, Calif), Thor-
tec biventricular ventricular assist device (Thoratec Corp), Thoratec left ven-
ricular assist device (Thoratec), and Novacor device (WorldHeart, Oakland,
alif), respectively. Twenty cerebrovascular accidents (42%) occurred in pa-
ients with infections. The mean white blood cell count at the cerebrovascular
ccident was greater than the normal range in patients with infection (12,900/
m3) and without infection (9500/mm3). The mean maximum amplitude of the
hrombelastogram in the presence of infection (63.6 mm) was higher than that
n the absence of infection (60.7 mm) (P  .0309).
onclusions: The risk of cerebrovascular accident increases with a longer ven-
ricular assist device support period. Infection may activate platelet function and
redispose the patient to a cerebrovascular accident. An elevation of the white
lood cell count may also exacerbate the risk of cerebrovascular accident even
n patients without infection. Selection of device type, prevention of infection,
nd meticulous control of anticoagulation are key to preventing cerebrovascular
ccident.
erebrovascular accident (CVA) is a devastating complication after ventric-
ular assist device (VAD) implantation. Investigators have reported that the
incidence of CVA in patients with a VAD ranges from 14% to 47%.1-3 The
ncidence of CVA was 1.6% to 4.6% after cardiac surgery, including coronary artery
ypass grafting and valve surgery. Several authors have reported risk factors for
vascular Surgery ● July 2007
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PVA: older age, female sex, history of CVA, peripheral
ascular disease, diabetes, hypertension, renal insufficiency,
trial fibrillation, previous cardiac surgery, preoperative in-
ection, prolonged cardiopulmonary bypass time, need for
ntraoperative hemofiltration, and high transfusion require-
ent.4-6 However, these risk factors are not always the same
s those in patients receiving VAD, and the mechanism of
VA is not fully understood. In the era of destination
herapy with a VAD, a solution for this complication is
mportant.
aterials and Methods
rom January 2000 to September 2005, 124 patients (98 males,
ge 7–72 years, mean 49.6 15.6 years) underwent VAD implan-
ation at the University of Pittsburgh Medical Center. We have
een developing our artificial heart program since 1986 and have
erformed implantation in more than 300 patients. Because Nova-
or continued to change its conduit and valve until 2000 to prevent
VA (as described later), and the outcome of patients who re-
eived a VAD improved after 2000 because of some modifications
ncluding anticoagulation and wound care,7 we collected data after
000 to simplify the comparison among devices. The preoperative
iagnoses were idiopathic cardiomyopathy in 36 patients (29%),
schemic cardiomyopathy in 36 patients (29%), acute cardiogenic
hock including acute myocardial infarction and postcardiotomy
ailure in 33 patients (27%), and other causes in 19 patients (15%).
ixty-four patients received a left ventricular assist device
LVAD), including 22 HeartMate left ventricular assist systems
Thoratec Corp, Pleasanton, Calif), 19 Thoratec LVADs (Thoratec
orp), 5 Thoratec implantable ventricular assist devices, 13 No-
acor devices (WorldHeart Inc, Oakland, Calif), and 5 HeartMate
I devices (Thoratec Corporation), whereas 60 patients underwent
iventricular assist device (BiVAD) implantation with 57 Thoratec
iVADs and 3 HeartMate left ventricular assist systems followed
y a Thoratec right ventricular assist device because of delayed
ight ventricular failure.
election of Device Type
election of the device was made on the basis of the patients’
reoperative hemodynamics. We have used the BiVAD strategi-
ally in the last 10 years in patients with significant right ventric-
Abbreviations and Acronyms
CVA  cerebrovascular accident
HIT  heparin-induced thrombocytopenia
INR  international normalized ratio
LVAD left ventricular assist device
MA maximum amplitude
POD  postoperative day
PTT  prothrombin time
TEG  thromboelastogram
TIA  transient ischemic attack
VAD  ventricular assist devicelar dysfunction and in patients in whom we believed the risk of b
The Journal of Thoracicight ventricular failure would be high perioperatively on the basis
f our early experience using a single-ventricle strategy.7 Patients
ho had the following conditions underwent BiVAD implantation:
cute cardiogenic shock with multiorgan failure with coagulopa-
hy, intractable ventricular arrhythmia or persistent ventricular
brillation, severe right ventricular dysfunction characterized by
entral venous pressure greater than 18 mm Hg and/or mean
ulmonary artery pressure less than 25 mm Hg or diastolic pul-
onary artery pressure less than 15 mm Hg on inotropic support
nd an intraaortic balloon pump, giant cell myocarditis, acute
iventricular myocardial infarction with or without a ventricular
eptal defect, acute biventricular postcardiotomy failure, and
VAD flow less than 2.0 L/min/m2 and central venous pressure
reater than 18 mm Hg after LVAD implantation in the operating
oom. In the selection of LVAD type, the Thoratec LVAD was
mplanted in smaller patients and those with acute cardiogenic
hock because implantable VADs were not feasible. In the selec-
ion between HeartMate and Novacor devices, we preferred to use
he Novacor device, which has a higher durability, for patients who
ad less chance of heart transplantation because of size mismatch,
lood type, or the existence of unacceptable antibodies. A pivotal
tudy of HeartMate II implantation was started from April 2004 if
he patient fitted its criteria.
ostoperative Anticoagulation
ostoperative anticoagulation in patients who underwent VAD
mplantation except with the HeartMate was started with dex-
ran 40% at 25 mL/h 6 hours after admission to the intensive
are unit if bleeding was less than 100 mL/h. Subsequently,
eparin was started when postoperative bleeding from the chest
ubes was less than 50 mL/h over 3 consecutive hours. The goal
or prothrombin time (PTT) was 40 to 51 seconds for at least the
rst 72 hours or until the risk of bleeding from more aggressive
nticoagulation was thought to be acceptable. Heparin was then
ncreased to maintain a PTT of 42 to 62 seconds. Coumadin was
ntroduced on postoperative day (POD) 10 to keep the interna-
ional normalized ratio (INR) between 2.5 and 3.5. Heparin was
iscontinued after obtaining an INR of at least 2.5. The philos-
phy of anticoagulation was to maintain heparin until the pa-
ient demonstrated a low risk of bleeding complications and
here had been a period of stable gastrointestinal tract function
nd diet. This usually occurred approximately 10 to 14 days
ostimplantation. A daily dose of 81 to 325 mg aspirin and/or
5 mg clopidogrel (Plavix, Sanofi-Aventis, Bridgewater, NJ)
as also started approximately 48 hours after implantation.
ince August 2004, aspirin and/or clopidogrel (Plavix) was
tarted if the maximum amplitude (MA) of the thromboelasto-
ram (TEG) was greater than 70 mm, and the dosage was
djusted to maintain MA at 60 to 70 mm. After discharge, the
NR was assessed a minimum of twice per week in stable
atients. In patients who received a HeartMate device, 81 to 325
g aspirin was started on POD 1 if bleeding was minimal. In
atients with atrial fibrillation with a HeartMate device, heparin
ollowed by Coumadin with the INR controlled at 2.0 to 3.0 was
iven after VAD implantation.
Data including patients’ medical history, demographics, and
lood parameters (white blood cell [WBC] count and TEG)
and Cardiovascular Surgery ● Volume 134, Number 1 115
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1
CSPere collected and retrospectively compared between the
roups who had postoperative CVAs including stroke and tran-
ient ischemic attack (TIA) (31 patients: CVA group) and those
ho did not have a postoperative CVA (93 patients: non-CVA
roup). Neurologic events were divided into 2 categories. A
troke was a focal brain event with signs and symptoms lasting
ore than 24 hours; TIA was a focal ischemic brain event
asting less than 24 hours with a negative brain image. This
tudy including patients’ data was approved by the Institutional
eview Board of the University of Pittsburgh Medical Center,
nd individual consent for the study was waived because indi-
ABLE 1. Patient demographics
CVA group %
o. of patients 31 25
ender
Male 24 77
Female 7 23
31 100
ge (y) 51.0  13.5
iagnosis
Ischemic cardiomyopathy 10 32
Idiopathic cardiomyopathy 8 26
Acute cardiogenic shock 9 29
Others 4 13
edical history
Atrial fibrillation 6 19
Abnormality of coagulation 4 13
Diabetes 8 26
Hypertension 14 45
Peripheral vascular disease 4 13
Previous CVA 1 3
mplanted VAD type
Thoratec BiVAD 13 42
Thoratec LVAD 4 13
Thoratec IVAD 1 3
Novacor 8 26
HeartMate 4 13
HeartMate II 1 3
HeartMate  Thoratec RVAD 0 0
31 100
AD support period
Mean (d) 228.5  169.1
30 d 1 3
30–120 d 8 26
121–365 d 17 55
365 d 5 16
evice outcomes
Transplantation 12 39
Weaned off device 2 6
Died on device 11 35
On device 6 19
iVAD, Biventricular assist device; IVAD, implantable ventricular assist de
VA, cerebrovascular accident; VAD, ventricular assist device; NS, not siidual patients were not identified. 4
16 The Journal of Thoracic and Cardiovascular Surgery ● Julynalysis
ata were expressed as mean  standard deviation. Data were
nalyzed univariately by unpaired Student t test for continuous
ariables and by chi-square or Fisher exact test for categoric
ariables between the groups using a commercially available sta-
istics package: Statview (ver5.0, SAS Institute Inc, Cary, NC).
esults
hirty-one patients (25%) had 48 CVAs, including 31
trokes and 17 TIAs after VAD implantation (Table 1). The
ean age was 51.0  13.5 years in the CVA group and
n-CVA group % P value Total %
93 75 124
74 80 NS 98 79
19 20 NS 26 21
93 100 124 100
8.1  16.3 .3747 49.6  15.6
26 28 NS 36 29
28 30 NS 36 29
24 26 NS 33 27
15 16 NS 19 15
24 26 NS 30 24
1 1 .0138 5 4
24 26 NS 32 26
25 27 NS 39 31
10 11 NS 14 11
5 5 NS 6 5
44 47 57 46
15 16 19 15
4 4 5 4
5 5 13 10
18 19 22 18
4 4 5 4
3 3 3 2
93 100 124 100
9.4  86.0 .0001
29 31
35 38
27 29
2 2
58 62 70 56
8 9 10 8
20 22 31 25
7 8 13 10
LVAD, left ventricular assist device; RVAD, right ventricular assist device;
ant.No
4
8
vice;8.1  16.3 years in the non-CVA group (P  .3747).
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Phirty-one patients with CVA included 13 with Thoratec
iVADs, 8 with Novacor devices, 4 with Thoratec LVADs,
with HeartMate devices, 1 with a Thoratec implantable
entricular assist device, and 1 with a HeartMate II device.
here was no significant difference between the CVA and
on-CVA groups in medical history, including atrial fibril-
ation (P .6291), diabetes (P .9999), hypertension (P
0744), peripheral vascular disease (P  .7481), and previ-
us CVA (P  .9999). Abnormalities of the coagulation
ystem including heparin-induced thrombocytopenia (HIT)
nd lupus anticoagulant were found in 4 patients and 1
atient in the CVA and non-CVA groups, respectively (P
0138). Three of 4 patients with lupus anticoagulant had
ultiple CVAs; a patient with a Thoratec LVAD had 3
VAs on PODs 85, 93, and 94, a patient with a Thoratec
iVAD had 2 CVAs on PODs 32 and 559, and a patient
ith a Novacor device had 2 CVAs on PODs 208 and 216.
patient with HIT with a Thoratec LVAD had 2 CVAs on
ODs 8 and 118. Mean VAD support period was 228.5 
69.1 days (range: 8–625 days) and 89.4  86.0 days
range: 0–368 days) in the CVA and non-CVA groups,
espectively (P  .0001). The mean period from implanta-
ion to the first CVA onset was 62.4 days, and 66% of CVAs
ccurred within 4 months (30 days: 31%, 31–120 days:
5%, 121–365 days: 31%, 365 days: 3%). The results of
ach device are shown in Table 2. Actuarial freedom from
VA at 6 months was 75%, 64%, 63%, and 33% for the
eartMate device, Thoratec BiVAD, Thoratec LVAD, and
he Novacor device, respectively (Figure 1). The mean
ABLE 2. Device outcomes in each device
VA
Thoratec
BiVAD Thoratec LVAD
Thoratec
IVAD
     
o. of patients 13 44 4 15 1 4
ean VAD support (d) 254 78 145 94 43 86
range) 8–625 0–259 43–204 9–282 18–250 4
evice outcome
Transplant 6 25 1 11 0 2
Died on device 6 13 1 2 0 0
Weaned from
device
0 5 1 2 1 1
On device 1 1 1 0 0 1
ause of death
CVA 2 0 0 1 0 0
Infection 3 0 1 1 0 0
Multiorgan failure 0 10 0 0 0 0
Respiratory failure 1 1 0 0 0 0
Liver failure 0 1 0 0 0 0
Graft failure 0 1 0 0 0 0
Unknown 0 0 0 0 0 0
iVAD, Biventricular assist device; LVAD, left ventricular assist device; IVAD, implant
ccident.ncidence of stroke with all devices was 0.879 per patient- B
The Journal of Thoracicear, and the results were 1.023, 0.976, 1.568, and 1.579 for
he HeartMate device, Thoratec BiVAD, Thoratec LVAD,
nd Novacor device, respectively. Detailed data on CVA are
hown in Table 3. The 31 patients with stroke included 19
ith embolism (61%), 8 with hemorrhage (26%), and 4 with
nknown causes (13%). CVA significantly affected the de-
ice outcome (Table 1). In the non-CVA group, 58 of 93
atients (62%) underwent heart transplantation, whereas
igure 1. Actuarial freedom from CVA in each VAD. CVA, cere-
rovascular accident; VAD, ventricular assist device; BiVAD,
vacor HeartMate
HeartMate
II
HeartMate 
Thoratec
RVAD All devices
        
5 4 18 1 4 0 3 31 93
106 257 121 69 30 n/a 102 229 89
41–223 40–598 3–368 20–48 17–229 8–625 0–368
3 1 14 0 1 0 2 12 58
1 2 2 1 1 0 1 11 20
0 0 0 0 0 0 0 2 8
1 1 2 0 2 0 0 6 7
0 1 0 1 0 0 0 5 1
0 0 1 0 0 0 0 4 2
0 0 0 0 1 0 1 0 12
1 0 0 0 0 0 0 1 2
0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 1
0 1 1 0 0 0 0 1 1
entricular assist device; RVAD, right ventricular assist device; CVA, cerebrovascularNo

8
223
1–428
4
1
0
3
1
0
0
0
0
0
0iventricular assist device; LVAD, left ventricular assist device.
and Cardiovascular Surgery ● Volume 134, Number 1 117
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1
CSPnly 12 of 31 patients (39%) underwent heart transplanta-
ion in the CVA group (P .0354). Mortality was higher in
he CVA group (11 patients, 36%) than in the non-CVA
roup (20 patients, 21%) (P  .1511). In the non-CVA
roup, 12 patients (60%), including 10 with BiVADs, died
f multiorgan failure without CVA. This means that patients
ho received BiVAD were too sick to recover. In the CVA
roup, 5 of 11 patients (45%) died of CVA itself, and no
atient died of multiorgan failure, which implies that CVA
irectly affected the mortality after VAD implantation. The
etails of the device outcome and cause of death for each
evice are shown in Table 2.
An infection developed in 27 of 31 patients (87%) in the
VA group, including 23 bloodstream, 20 respiratory, 29
rinary tract, and 15 device-related infections during VAD
upport, whereas 51 of 93 patients (55%) in the non-CVA
roup had an infection, including 26 bloodstream, 28 respi-
atory, 29 urinary tract, and 24 device-related infections (P
.0012). Twenty CVAs (42%) occurred during infection,
ncluding 7 bloodstream, 5 device-related, 4 urinary tract,
nd 4 respiratory infections. The mean WBC count at the
ime of CVA exceeded the normal range in patients with
nfection (12,900/mm3) and without infection (9500/mm3)
P  .7256). Information on the infections in each patient
ith CVA (infection source and WBC count) when they had
 CVA are shown in Table 4.
Anticoagulation and antiplatelet therapy for each patient
t the time of CVA are shown in Table 4. Twenty-two of 48
VAs (46%) occurred when anticoagulation therapy was
ut of the therapeutic range, including 9 cases of hyper-
herapeutic and 13 cases of hypotherapeutic anticoagulation
ue to bleeding, accident, or patient noncompliance. Not all
ABLE 3. Demographics of patients with cerebrovascular
Thoratec BiVAD %
Thoratec
LVAD %
Thoratec
IVAD %
o. of patients with
CVA
13 4 1
ncidence of stroke/
patient-year
0.976 1.568 0.941
ype of CVA
Stroke 13 72 7 78 0
TIA 5 28 2 22 1 1
Total 18 100 9 100 1 1
ource of CVA
Embolism 7 39 5 56 0
Hemorrhage 4 22 3 33 0
Unknown 7 39 1 11 1 1
iming of CVA onset
30 d 6 33 2 22 0
30–120 d 7 39 4 44 1 1
121–365 d 4 22 3 33 0
365 d 1 6 0 0 0
iVAD, Biventricular assist device; LVAD, left ventricular assist device; IVAD, implantaf the cases of hypotherapeutic and hypertherapeutic anti- s
18 The Journal of Thoracic and Cardiovascular Surgery ● Julyoagulation resulted in embolism and hemorrhage, respec-
ively. Despite appropriate anticoagulation therapy, the rest
f the patients experienced CVAs. The mean MA of TEG in
eriods with infection (63.6 9.1 mm) was higher than that
n those without infection (60.7  7.4 mm) (P  .0309).
iscussion
VA is one of the major complications after VAD implan-
ation. The Mechanical Circulatory Support Device Data-
ase of the International Society for Heart and Lung Trans-
lantation in 2005 reported that 14% of patients with VADs
ad neurologic dysfunction, and there were 18 cumulative
hromboembolic events per 100 patients at 6 months after
evice implantation.1 Lazar and colleagues8 reported that
6% of patients with an LVAD had a stroke, with a rate of
.19 per year. Other authors reported 14% to 47% CVA
ccurrence.1–3 In our study, CVA occurred in 25% of pa-
ients and greatly affected the device outcomes, including
eart transplantation and mortality. Therefore, the preven-
ion of CVA is key to obtaining a good outcome after VAD
mplantation. The incidence of CVA was 1.6% to 4.6% after
ardiac surgery, including coronary artery bypass grafting
nd valve surgery.4–6 Risk factors in patients who under-
ent cardiac surgery were not always the same as those in
atients receiving VAD. In our study, common risk factors
or CVA in association with cardiac surgery (ie, diabetes,
ypertension, atrial fibrillation, peripheral vascular disease,
nd history of CVA) were not risk factors for CVA after
AD implantation, which may imply that patients who
ndergo VAD need particular strategies to prevent CVA.
Schmid and associates2 reported that the incidence of
VA did not correlate strongly with the duration of VAD
dent
Novacor % HeartMate % HeartMate II %
All
devices %
8 4 1 31
1.579 1.023 1.028 0.879
7 70 5 56 0 0 32 67
3 30 4 44 1 100 16 33
10 100 9 100 1 100 48 100
5 50 3 33 0 0 20 42
3 30 1 11 0 0 11 23
2 20 5 56 1 100 17 35
4 40 3 33 0 0 15 31
2 20 2 22 1 100 17 35
4 40 4 44 0 0 15 31
0 0 0 0 0 0 1 2
tricular assist device; CVA, cerebrovascular accident; TIA, transient ischemic attack.acci
0
00
00
0
0
00
0
00
0
0upport, and that the majority of CVAs (43%) occurred
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Puring the interval from 30 to 100 days after VAD implan-
ation. In our study, the mean VAD support period in the
VA group (228.5 days) was significantly longer than that
n the non-CVA group (89.4 days). There is no doubt that
he longer the VAD support period, the higher the risk of
VA, but we should pay attention to the fact that the
on-CVA group included 20 patients with a device who
ainly died of multiorgan failure (60%) with a mean sup-
ort period of 61 days, and 10 of 20 patients died within 30
ays after VAD implantation. This decreased not only the
ean VAD support period but also the chance of CVA
uring VAD support. Sixty-six percent of CVAs occurred
ithin 4 months after VAD implantation, and then the risk
f CVA decreased as shown in Figure 1. This means that
ppropriate anticoagulation in the early phase after VAD
mplantation is important. Also, 46% of CVAs occurred
hen anticoagulation control was out of the therapeutic
ange (Table 4). Embolism (42%) was predominant over
emorrhage (23%) as a cause of CVA; however, it would be
remature to emphasize strong anticoagulation immediately
fter VAD implantation because embolism and hemorrhage
re always directly opposed phenomena. Tailor-made anti-
oagulation therapy depending on the patient and the device
s required to prevent CVA, as described below.
In terms of the difference in actuarial freedom from CVA
mong all VADs, the HeartMate device was superior to
thers despite a mild anticoagulation strategy with aspirin
lone. In accordance with other authors’ data, Novacor had
high CVA risk despite aggressive anticoagulation and
hanges in the conduit and valve.2,3,9-12 Novacor used a
ooley double-velour graft (Cooley, Meadox Medical, Oak-
and, NJ) for the inflow and outflow conduits until 1988,
hich were woven, low-porosity, crimped, unsupported
olyester prostheses. Suboptimal mural flow in combination
ith radial pulsation made it prone to develop a poorly
ttached, friable pannus that could cause particulate emboli.
rom 1998 to 2000, the Vasculour II (Sulzer Vascutek,
enfrewshire, Scotland) was used for the inflow conduit.
his conduit was made of knitted gel-sealed uncrimped
olyester and was integrally supported with a polypropylene
tent. The incidence of CVA became significantly less with
he Vasculour II conduit (6%–12%) than with the Cooley
onduit (21%–23%).13,14 However, a thin, adherent pannus
ould be observed in the Vasculour II conduit. Two lengths
f conduits, 6 cm and 9 cm, were available, but no signif-
cant difference in the incidence of CVA was found between
asculour II conduit lengths.14 The expanded polytetrafluo-
oethylene (ePTFE, Edwards Lifesciences, Irvine, Calif)
nflow conduit was introduced in 2000. This conduit has an
ninterrupted luminal surface and is not penetrated by su-
ures. An outer impermeable fluorinated ethylene-propylene
oating reduces the risk of leaks or bleeding through the
all, blocks transmural penetration by inflammatory medi- l
The Journal of Thoracictors, and prevents adhesions; the fibrous tissue capsule
eadily separates. Two lengths of conduits, 6 cm and 9 cm,
re available. A significant decrease in CVA was found in
atients who received an ePTFE conduit, with a linearized
ate of 0.025 events/patient-month versus 0.034 events/
atient-month in patients who received a Vasculour II con-
uit (rate ratio: 0.76).15 Also, a bovine pericardial valve was
sed initially; however, Novacor implemented a change to a
orcine xenograft valve that resulted in better flow charac-
eristics. Because our data were collected since 2000, all our
atients with Novacor devices received an ePTFE inflow
onduit and porcine xenograft.
There was a discrepancy between the results of actuarial
reedom from CVA and the incidence of stroke per patient-
ear of device support in patients with Thoratec LVADs and
ovacor devices. In actuarial freedom from CVA at 6
onths, the Thoratec LVAD (63%) showed better results
han the Novacor device (33%), but the incidence of stroke
er patient-year of device support was almost the same:
.568 with the Thoratec LVAD and 1.579 with the Novacor
evice. Multiple CVAs during Thoratec LVAD support in a
atient with lupus anticoagulant (3 CVAs) and a patient
ith HIT (2 CVAs) increased the incidence of stroke per
atient-year. This means that even in patients who receive a
AD with a higher rate of freedom from CVA, coagulation
bnormalities may increase the risk of CVA. Abnormal
oagulation system diseases, such as HIT and lupus antico-
gulant, are devastating problems in patients with VAD and
ore challenging to control appropriately after VAD im-
lantation. HIT is caused by the development of an immu-
oglobulin (Ig)G antibody that recognizes multimolecular
omplexes of platelet factor 4 and heparin. If HIT develops,
he platelet count typically begins to decrease 5 to 10 days
fter starting heparin. Half of the patients will have associ-
ted thrombosis. The incidence of HIT is approximately less
han 1% in medical patients but is higher in surgical patients
5% in orthopedic patients).16 Lupus anticoagulant is caused
y antiphospholipid antibodies (IgG, IgM, or a mixture of
oth) and is associated with cerebral, deep venous, or renal
hromboses, as well as pulmonary emboli or arterial occlu-
ions, particularly stroke. Some 2% to 4% of the US pop-
lation is affected, and the incidence of thrombotic compli-
ations in patients with lupus anticoagulant ranges from 5%
o 20%. Reports indicate that lupus anticoagulant is found in
% to 14% of patients with deep venous thrombosis and in
pproximately one third of patients with stroke who are
ged less than 50 years. There is also evidence that the type
f recurrent thrombotic event, venous or arterial, tends to be
ersistent over time in the same patient. Lupus anticoagu-
ant is characterized by a prolonged activated partial throm-
oplastin time. In our series, uncontrollable thromboem-
olic events were experienced, including CVA, pulmonary,
iver, and renal emboli in 1 patient with HIT and in 3
and Cardiovascular Surgery ● Volume 134, Number 1 119
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CSPABLE 4. Data at the time of cerebrovascular accident in each patient
atient Device type
Period from
implant to
CVA (d)
Type of
CVA
Source of
CVA
Antiplatelet
therapy
Anticoagulation
therapy INR PTT
Anticoagulation
control Infection
WBC
count
(1000)
1 HeartMate 110 TIA Unknown Aspirin 325 mg BID None 1.2 None 5.4
2 HeartMate 1 Stroke Embolism None None 1.4 None 4.9
299 TIA Unknown Aspirin 325 mg BID None 1.0 None 11.7
324 TIA Unknown Aspirin 325 mg QD Heparin
Coumadin
1.3 32.5 Low None 7.9
339 Stroke Unknown Aspirin 325 mg BID
Clopidogrel 75 mg
QD
None 1.1 None 9.3
351 Stroke Hemorrhage Aspirin 325 mg BID
Clopidogrel 75 mg
BID
Heparin 1.1 35.1 Low None 11.6
3 HeartMate 67 TIA Unknown Aspirin 325 mg BID Coumadin 2.2 None 5.6
4 HeartMate 5 Stroke Embolism None None 1.1 None 14.8
20 Stroke Embolism None None 1.2 None 8.1
5 HeartMate II 64 TIA Unknown Aspirin 81 mg QD
Dipyridamole 75
mg TID
Coumadin 2.7 Blood
Urine
11.9
6 Novacor 23 Stroke Unknown Aspirin 81 mg QD
Clopidogrel 75 mg
QD
Heparin 14.2 Low None 6.7
7 Novacor 16 Stroke Embolism Aspirin 81 mg QD
Clopidogrel 75 mg
QD
Heparin
Coumadin
1.5 65.4 High None 10.6
8 Novacor 20 Stroke Hemorrhage Aspirin 81 mg QD
Clopidogrel 75 mg
QD
Heparin 81.0 High None 10.4
9 Novacor 153 Stroke Embolism Aspirin 325 mg QD Heparin 1.3 68.0 High Blood 19.2
166 TIA Hemorrhage Aspirin 325 mg QD Heparin 1.2 67.9 High Blood 7.5
10 Novacor 106 TIA Unknown None due to
bladder bleeding
Heparin 1.1 40.0 Low None 4.3
11* Novacor 208 Stroke Embolism Aspirin 81 mg QD
Clopidogrel 75 mg
QD
Coumadin 2.2 Low Device 6.5
216 Stroke Embolism None Heparin 1.2 53.4 Device 9.8
12 Novacor 17 TIA Embolism Aspirin 81 mg QD Heparin 1.3 34.6 Low Respiratory 15.7
13 Novacor 36 Stroke Hemorrhage Aspirin 81 mg QD Heparin 55.2 Device 8.4
14 Thoratec BiVAD 65 TIA Unknown Aspirin 81 mg QD Coumadin 3.8 High None 6.9
66 TIA Unknown Aspirin 81 mg QD Coumadin 3.4 None n/d
70 Stroke Hemorrhage Aspirin 81 mg QD Coumadin 3.5 None n/d
15 Thoratec BiVAD 26 Stroke Unknown Aspirin 325 mg QD Coumadin 2.3 Low None 9.3
16 Thoratec BiVAD 25 TIA Unknown None due to
recent bleeding
Dextran 1.2 33.7 Low Respiratory 8.6
17 Thoratec BiVAD 6 Stroke Hemorrhage Aspirin 325 mg QD Heparin 53.7 Respiratory 21.5
18 Thoratec BiVAD 0 Stroke Unknown None due to
immediately after
surgery
Dextran 1.1 Low None 17.5
19 Thoratec BiVAD 4 Stroke Embolism None Heparin 56.3 None 17.7
86 Stroke Embolism None Heparin 28.9 Low None 14.6
20 Thoratec BiVAD 7 Stroke Embolism None Heparin 45.6 Respiratory 19.9
21 Thoratec BiVAD 330 Stroke Embolism Aspirin 325 mg QD Coumadin 3.9 High Blood 13.1
22 Thoratec BiVAD 59 TIA Unknown Aspirin 81 mg QD Heparin 1.2 43.2 Urine 12.2
23* Thoratec BiVAD 32 TIA Unknown Aspirin 325 mg QD Heparin
Coumadin
1.1 55.8 None 9.1
559 Stroke Embolism Aspirin 325 mg QD
Clopidogrel 75 mg
QD
Heparin 1.2 39.3 Low Blood 7.5
24 Thoratec BiVAD 41 Stroke Hemorrhage None Heparin
Coumadin
1.3 49.6 None 9.425 Thoratec BiVAD 133 Stroke Hemorrhage None Coumadin 3.0 Urine 14.2
20 The Journal of Thoracic and Cardiovascular Surgery ● July 2007
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CS
Patients with lupus anticoagulant after VAD implantation.
n the basis of our experiences, we started preoperative
ests for coagulation abnormalities, including HIT, lupus
nticoagulant, factor V Leiden, antithrombin III deficiency,
rotein C deficiency, protein S deficiency, prothrombin
ene mutation, hyperhomocysteinemia, and carotid artery
oppler for all patients and a head computed tomography
can for patients who had a history of CVA or an audible
ruit of the carotid artery before VAD implantation. If a
atient had positive results from these tests, the Novacor
evice was not selected because CVA greatly affects device
utcomes, including heart transplantation achievement and
ortality. In patients with HIT, postoperative anticoagula-
ion therapy should be done with bivalirudin or hirudin,17,18
ollowed by Coumadin with an INR of 2.5 to 3.5 for all
ypes of VADs. If a patient has lupus anticoagulant, post-
perative anticoagulation is controlled with higher PTT
46–80 seconds) and INR (3.0–4.0) levels.
The selection of VAD type is a key to obtaining excellent
utcomes. In our institute, the BiVAD was selected strate-
ically for patients with significant right ventricular dys-
unction and for patients who we believed were at risk of
ight ventricular failure peri- and postoperatively.7 Because
his study showed that the incidence of CVA in patients
ith a Thoratec BiVAD was acceptably low, we do not
hink we have to question our BiVAD strategy with respect
o CVA risk. It is reasonable to use the Thoratec LVAD, an
xtracorporeal type of VAD, for small patients and patients
n acute cardiogenic shock because of its acceptable low
VA rate. Implantable LVAD type selection is still puz-
ABLE 4. Continued
atient Device type
Period from
implant to
CVA (d)
Type of
CVA
Source of
CVA
Antipla
thera
26 Thoratec BiVAD 131 Stroke Embolism Aspirin 81 m
196 Stroke Embolism Aspirin 325
27 Thoratec IVAD 42 TIA Unknown None
28 Thoratec LVAD 103 Stroke Embolism Aspirin 81 m
29* Thoratec LVAD 85 TIA Hemorrhage Aspirin 81 m
93 TIA Hemorrhage None
94 Stroke Hemorrhage None
30† Thoratec LVAD 8 Stroke Embolism None
188 Stroke Embolism Aspirin 325
31 Thoratec LVAD 9 Stroke Embolism None
192 Stroke Unknown Aspirin 325
226 Stroke Embolism Aspirin 325
Clopidogrel
QD
VA, Cerebrovascular accident; INR, international normalized ratio; PTT, prothrombin
ata; QD, once per day; TIA, transient ischemic attack; TID, 3 times per day; IVAD, imp
ssist device; IVAD, implantable ventricular assist device; ASA, acetylsalicylic acid.ling because of the variable durability (less with the Heart- s
The Journal of Thoracicate device) and CVA rate (higher with the Novacor de-
ice). Because the freedom from CVA of the HeartMate
evice was reliably higher than that of the Novacor device,
nd CVA affected the outcome after VAD implantation, the
eartMate device would be desirable for all patients, espe-
ially in those with coagulation abnormalities. The Novacor
evice may be desirable for patients without coagulation
bnormalities and for patients who have less possibility of
ndergoing heart transplantation because of size mismatch,
lood type, or the existence of unacceptable antibodies and
ho undergo VAD implantation as destination therapy. It
ay be too early to say because we dealt with a small
umber of HeartMate II cases, but the HeartMate II device
ay become the best VAD in the future because it can be
xpected to have both a low CVA rate because of the same
nternal surface texture and conduits of the HeartMate de-
ice and a high durability because of its design without
alves.
TEG was introduced at our institute in August 2004 for
eticulous anticoagulation therapy in patients on VAD.
EG is a bedside monitor of coagulation and traces the
iscoelasticity of the clot forming between a suspended pin
nd a cuvette wall; therefore, the result may be affected by
arious plasma and cellular components of coagulation. The
ollowing parameters were obtained from the TEG trace: R
ime: period of time from initiation of the test to the start of
he trace and represents initial fibrin formation; alpha: the
ngle between the line in the middle of the TEG tracing and
he line tangential to the developing TEG tracing and rep-
esents the kinetics of fibrin cross-linking; MA: reflects
Anticoagulation
therapy INR PTT
Anticoagulation
control Infection
WBC
count
(1000)
Coumadin 3.1 Device 7.0
Coumadin 4.1 High Device 8.2
Heparin 46.2 Blood 6.0
Coumadin 2.9 None 8.4
Coumadin 3.2 None 7.3
Heparin
Coumadin
2.1 38.4 Low None 8.0
Heparin
Coumadin
1.6 83.2 High None 8.0
Bivalirudin 1.7 35.0 Urine 39.0
Heparin
Coumadin
1.5 43.7 None 12.0
Heparin 1.1 52.2 Respiratory 15.2
Coumadin 3.7 High None n/d
Coumadin 2.3 Low Blood 6.8
WBC, white blood cell; BID, twice per day; CVA, cerebrovascular accident; n/d, no
le ventricular assist device; LVAD, left ventricular assist device; BiVAD, biventricular
s anticoagulant; †HIT.telet
py
g QD
mg QD
g QD
g QD
mg QD
mg QD
mg QD
75 mg
time;
lantabtrength of a clot that is dependent on the number and
and Cardiovascular Surgery ● Volume 134, Number 1 121
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CSPunction of platelets and its interaction with fibrin but is
nsensitive to the effect of aspirin; LY-30: measures the
ate of amplitude reduction 30 minutes after MA and
epresents the stability of the clot. We especially focused
n the MA level to examine platelet function after VAD
mplantation. It is too early to state conclusively because
f the small number of experiences at our institute, but
e observed a fluctuating MA level immediately after
AD implantation and stabilized MA level in the late
hase. This phenomenon may support our result that 66%
f CVAs occurred within 4 months after VAD implanta-
ion. We consider that tailor-made antiplatelet therapy
ased on TEG may be effective to prevent CVA in
atients with a VAD.
The relationship between CVA and a high WBC count
nd/or infection has been studied. Several investigators
eported an association between CVA and elevated WBC
ount and C-reactive protein.19-22 Albert and col-
eagues23 reported that WBC count was significantly
igher preoperatively and postoperatively in patients
ith CVA. The risk of perioperative CVA increased
tarting with a preoperative WBC count of 9000/ mm3 (P
.044) and further increased at higher WBC counts. In
ur study, patients with CVA had a high WBC count
xceeding the normal range (9000/mm3) regardless of
he presence or absence of infection (patients with infec-
ion: 12,900/mm3; patients without infection 9500/mm3).
urthermore, 42% of CVAs occurred in patients with
nfection. The relationship between infection and CVA is
till not fully understood. The basic mechanism may be
ltered rheology caused by an increased fibrinogen level
nduced by infection24 or blood viscosity, erythrocyte
igidity, fibrinogen concentration,25 protein C,26 protein
, and platelet aggregation.27 Grau and colleagues21 re-
orted recent bacterial and viral infection as a risk factor
or CVA. Recently, we routinely checked not only INR
ut also TEG, controlling the level of MA at approxi-
ately 60 to 70 with aspirin and/or clopidogrel (Plavix).
ur data showed that mean MA in periods with infection
63.6 mm) was higher than that without infection (60.7
m) (P  .0309) under the same protocol, which may
linically support the hypothesis that infection activates
latelet aggregation. We check TEG when a patient has
ymptoms of CVA or infection to adjust antiplatelet
herapy.
imitations
imitations of this study include those related to a retro-
pectively performed analysis at a single center. Not all
ata from every patient were available or data could not
e obtained because of the critical illness of the patients
tudied. The number of patients was relatively low.
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